GlassScriptPhysician profile
Eugenio Moises Guevara
NPI 1033305701
$8,561.48
in general payments reported to CMS, 2019-2025
20 companies · $1,399 in 2025
The $1,399 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,400 · 2020: $914 · 2021: $933 · 2022: $1,755 · 2023: $742 · 2024: $1,417 · 2025: $1,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,097 · Travel and Lodging: $438 · Education: $23.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,096.74 |
| Travel and Lodging | $438.37 |
| Education | $23.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,642.59 | 2019-2025 | Briviact, Nayzilam |
| Neurocrine Biosciences, INC. | $1,217.82 | 2020-2025 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $1,067.33 | 2019-2025 | Nuplazid |
| Adamas Pharmaceuticals, INC. | $654.09 | 2019-2021 | |
| Medtronic, INC. | $514.53 | 2022-2025 | Intellis Adaptivestim |
| Amneal Pharmaceuticals LLC | $497.67 | 2020-2025 | Crexont, Rytary, Ongentys |
| Eisai INC. | $313.95 | 2021-2025 | |
| Ge Healthcare | $305.84 | 2019-2023 | |
| Catalyst Pharmaceuticals, INC. | $277.24 | 2023-2024 | Fycompa |
| Avion Pharmaceuticals | $157.58 | 2022 | |
| Kyowa Kirin, INC. | $154.16 | 2020 | |
| Acorda Therapeutics, INC | $138.77 | 2019-2020 | |
| Si-Bone, INC. | $133.72 | 2022 | |
| Biogen, INC. | $127.14 | 2024-2025 | Leqembi |
| Teva Pharmaceuticals USA, INC. | $122.88 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aprecia Pharmaceuticals, LLC | $98.28 | 2022 | |
| Pfizer INC. | $62.97 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $41.32 | 2020 | |
| Vertical Pharmaceuticals, LLC | $17.76 | 2019 | |
| Merz Pharmaceuticals, LLC | $15.84 | 2024 | Inbrija |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugenio Guevara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.